Balaji V, Seshiah V, Ashtalakshmi G, Ramanan S G, Janarthinakani M
Dr. V. Seshiah Diabetes Research Institute, Dr. V. Balaji Care Centre, Chennai, Tamil Nadu, India.
Cancer Research and Relief Trust, Chennai, Tamil Nadu, India.
Indian J Endocrinol Metab. 2014 May;18(3):425-7. doi: 10.4103/2230-8210.131223.
This retrospective cohort study analyzed the clinical data of cancer patients conducted in a cancer hospital, Chennai to assess the correlation (if any) between use of antidiabetic agents including pioglitazone and the incidence of bladder cancer.
Totally, 5079 cancer patients' with and without diabetes were included and analyzed in this retrospective study.
A total of 1077 patient data were screened out of a total of 5079. A total of 20 patients were found to have bladder cancer. Out of 1077 patients, 31 were pioglitazone users on the drug for not less than 2 years. The remaining 1046 were on other drugs other than pioglitazone. It is observed that 1 out of 31 developed bladder cancer in the pioglitazone group 19 out of 1046 developed bladder cancer in the nonpioglitazone group. The result of the analysis indicates that there is no significant (P = 0.918) association between pioglitazone and bladder cancer.
In this retrospective study, the number of diabetic patients on pioglitazone with bladder cancer was fewer than the diabetic patients on other medications with the disease. Further, no link could be established between any specific drug use and bladder cancer. Least number of patients with bladder cancer was on pioglitazone, suggesting that pioglitazone alone cannot be considered a cause for increased incidence of bladder cancer in diabetic patients.
这项回顾性队列研究分析了在金奈一家癌症医院开展的癌症患者临床数据，以评估包括吡格列酮在内的抗糖尿病药物的使用与膀胱癌发病率之间的相关性（若存在）。
本项回顾性研究共纳入并分析了5079例患有和未患糖尿病的癌症患者。
在总共5079例患者数据中，共筛选出1077例。发现共有20例患者患有膀胱癌。在1077例患者中，31例为使用吡格列酮不少于2年的患者。其余1046例使用的是吡格列酮以外的其他药物。观察到吡格列酮组31例中有1例患膀胱癌，非吡格列酮组1046例中有19例患膀胱癌。分析结果表明，吡格列酮与膀胱癌之间无显著关联（P = 0.918）。
在这项回顾性研究中，患膀胱癌的使用吡格列酮的糖尿病患者数量少于患该疾病的使用其他药物的糖尿病患者。此外，无法在任何特定药物使用与膀胱癌之间建立联系。患膀胱癌的患者中使用吡格列酮的人数最少，这表明不能仅将吡格列酮视为糖尿病患者膀胱癌发病率增加 的原因。
